Anticancer drug discovery and pharmaceutical chemistry: A history

Clinical and Translational Oncology

Volumn 8, Issue 10, 2006, Pages 717-728

  Braña, Miguel F ^a,c   Sánchez Migallón, Ana ^b  

^a Madrid Spain   (Spain)

^b UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

^c NONE   (Spain)

Author keywords

Drug design; Drug discovery; Organic chemistry of anticancer drugs

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; DOCETAXEL; ELLIPTICINE; ETOPOSIDE; FLUOROURACIL; IMATINIB; INDIRUBIN; IRINOTECAN; MELPHALAN; MUSTARD GAS; NATURAL PRODUCT; NAVELBINE; NEW DRUG; PACLITAXEL; PODOPHYLLIN; PODOPHYLLOTOXIN; PODOPHYLLOTOXIN DERIVATIVE; PROCARBAZINE; TENIPOSIDE; TOPOTECAN; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; VINDESINE; ZINOSTATIN; BIOLOGICAL PRODUCT; DRUG;

DRUG CONFORMATION; DRUG DESIGN; DRUG METABOLISM; DRUG STRUCTURE; DRUG TARGETING; HIGH THROUGHPUT SCREENING; HISTORY; MOLECULAR MODEL; REVIEW; ANIMAL; CHEMICAL MODEL; CHEMISTRY; DRUG SCREENING; HUMAN; ORGANIC CHEMISTRY; PHARMACEUTICS;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; CHEMISTRY, ORGANIC; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG SCREENING ASSAYS, ANTITUMOR; HISTORY, 20TH CENTURY; HUMANS; MODELS, CHEMICAL; PHARMACEUTICAL PREPARATIONS; TECHNOLOGY, PHARMACEUTICAL;

EID: 39049189914     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-006-0118-5     Document Type: Review

References (37)

1. Humblet C, Marshall GR. Pharmacophore identification and receptor mapping. Annu Rep Med Chem. 1980;15:267-76.
2. Ariens E. Drug Design. Vol 1. Academic Press, London, 1971.
3. Sneader W. Drug Discovery. A history. J Wiley, Chichester, 2005.
4. Monge A. Personal communication.
5. The most paradigmatic example in medicinal chemistry is penicillin. The availability of 6-APA by fermentation opened the new world of antibiotic β-lactamics.
6. Noble RI, Beer CT, Cutts JH. Role of chance observations in chemotherapy: Vinca rosea. Ann NY Acad Sci. 1958;76:882-94.
7. Svoboda GH, Johnson IS, Gorman M, Neuss N. Current Status of research on the alkaloids of Vinca rosea Linn. (Catharanthus roseus G. Don). J Pharm Sci. 1962;51:707-20.
8. Hatwell JL, Schrecker AW. Components of podophyllin. V. The constitution of podo-phyllotoxin, J Am Chem Soc. 1951;73:2909-16.
9. Keller C, Khun M, von Wartburg A, Stähellin H. Mitosis-inhibiting natural products. 24. Synthesis and antimitotic activity of glyicosidic lignan derivatives related to podophyllotoxin. J Med Chem. 1971;14:936-40.
10. Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT. Plant antitumor agents. 1. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc. 1966;88:3888-90.
11. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem. 1985;260:14873-8.
12. Kingsbury WD, Boehm JC, Jakas DR, et al. Synthesis of water-soluble (aminoalkyl) camptothecin analogs: Inhibition of topoisomerase I and antitumor activity. J Med Chem. 1991;34:98-107.
13. Sawada S, Okajima S, Aiyama R, et al. Synthesis and antitumor activity of 20(S)-camptothecin derivatives; carbamate linked, water soluble derivatives of 7-ethyl-10-hydroxycampto-thecin. Chem Phar Bull. 1991;39:1446-50.
14. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by Taxol. Nature, 1979;277:665-7.
15. Wermuth CG. Strategies in the search for new lead compounds. In The practice of Medicinal Chemistry. Ed. GC Wermuth, Academic Press, London, 1996.
16. Zimmermann J, Buchdunger E, Mett H, Meyer T, Lydon NB, Traxler P. Phenylamino-pyrimidine (PAP) derivatives: A new class of potent and highly selective PDGF receptor autophosphorilation inhibitors. Bioorg Med Chem Lett. 1996;6:1221-6.
17. Gilman A, Philips FS. The biological actions and therapeutic application of β-chloro-ethyl amines and sulfides. Science. 1946;103:409-15.
18. Rosemberg B, van Camp L, Trosko JE, Mansour VH. Platinum compounds: A new class of potent antitumor agents. Nature 1969;222:385-6.
19. Pizarro AM, Vivienne PM, Navarro-Ranninger, Peter J. Hydrolysis Triggers Oxidation of Trans Diamine Platinum(II) Anticancer Complex. Angew Chem Int Ed. 2003;42:539-42.
20. Zee-Cheng RKY, Cheng CC. Antineoplastic agents. Structure-activity relationships study of bis(substituted aminoalkylamino) anthraquinones. J Med Chem. 1978;21:291-4.
21. Wunz TP, Dorr RT, Alberts DS, Tunget CL, Einspahr J, Milton S, Remers W. New antitumor agents containing the anthracene nucleus. J Med Chem. 1987;30:1313-21.
22. Griffiths C, Hall T, Saba Z. Preliminary trial of aminoglutetimida in breast cancer. Cancer. 1973;32:31-7.
23. Sosinski J, Thakar JH, Germain GS, Kuttesh JF, Houghton PJ. Cross-resistance to antitumor diarylsulfonylureas, and collateral sensitivity to mitochondrial toxins in a human cell line selected for resistance to the antitumor agentN-(5-indanylsulfonyl)-4-N′4-chlophenyl)urea. Mol Pharmacol. 1994;45:962-70.
24. Farber S, Diamond LK, Mercer RD, Sylvester RF, Wolff A. Temporari remission in acute leukemia in children produced by folic acid antagonists. New Engl J. Med. 1948;238:787-93.
25. Seeger D, Cosulich DB, Smith JM, Hulkist ME. Analogs of pterylglutamic acid III. 4-amino derivatives. J Am Chem Soc. 1949;71:765-6.
26. Elion GB, Burgi E. Hitchings. Studies on condensed pyrimidine system. IX. The synthesis of some 6-substituted purines. J Am Chem Soc. 1952;74:411-4.
27. Pratt WB, Ruddon RW, Ensminger WD, Maybaum J. The anticancer Drugs. 2nd ed. Oxford University Press. New York; 1994.
28. Heidelberger C, Chaudhuri NK, Dannemberg, et al. Fluorinated Pyrimidines, a new class of tumor/inhibitory compounds. Nature. 1957;179:663-6.
29. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H. Canc Res. 1998;58:685-90.
30. Carlisle CH, Crowfoot D. A determination of molecular symmetry in the α-β-diethyl-dibenzyl series. J Chem Soc. 1941. p. 6-9.
31. Braña MF, García ML, Miguel PD, Morán M. Multiresistencia a fármacos antitumor-rales. In Cancer. Ed. Barreno PG, Espinós D, Cascales M. Instituto de España. Madrid, 2003.
32. Arcamone FM, Animati F, Barbieri B, et al. Synthesis, DNA-binding properties, and antitumor activity of novel distamycin derivatives. J Med Chem. 1989;32:774-8.
33. Feigon J, Denny WA, Leupin W, Kearns DR. Interaction of antitumor drugs with natural DNA: 1H-NMR study of binding mode and kinetics. J Med Chem. 1984;27:450-65.
34. Hsiang Y-H, Jiang JB, Liu LF. Topoisomerase II-mediated DNA cleavage by Amona-fide and its structural analogs. Mol Pharmacol. 1989;36:371-6.
35. Rao KE, Krowicki K, Balzarini J, De Clerq E, Newman RA, Lown JW. Novellinked antiviral and antitumor agents related to netropsin-2: Synthesis and biological evaluation. In Actualités de Chimie Thérapeutique. Ed. C. Combet-Farnoux. 1991. p. 21-42.
36. Sobell HM, Reddy BS, Bhandary KK, Jain SC, Sakore TO. Organization of DNA in chromatin Proc Nat Acad Sci USA. 1976;73:3068-72.
37. Dancey JE, Chen HX. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nature Drug Discov. 2006;5:649-59.